$EYPT

EyePoint, Inc.

EyePoint is a clinical-stage biopharmaceutical company developing and commercializing therapies for serious retinal diseases. Its pipeline uses Durasert E, a bioerodible sustained-delivery technology for intraocular drug delivery. The lead candidate, DURAVYU, combines vorolanib with Durasert E and is being evaluated in Phase 3 trials for wet age-related macular degeneration and diabetic macular edema. EyePoint is also advancing EYP-2301, which delivers razuprotafib in Durasert E and is in preclinical development. EyePoint makes money through royalties on licensed products, including royalties from a partner’s sales of DURAVYU in Greater China. It also manufactures YUTIQ for its partner’s sales in China. EyePoint is headquartered in Watertown, Massachusetts, and has a commercial manufacturing facility in Northbridge, Massachusetts.

0
2
9

No SEC Form 4 filings for $EYPT in the last 30 days.

See all $EYPT insider activity →

EyePoint Pharma Earnings Call: DME Focus After Wet AMD Setback

EyePoint Pharma reported Q3 earnings, highlighting a setback in wet AMD trials and a 53% workforce reduction. Despite this, the company remains focused on DURAVYU for diabetic macular edema (DME), citing positive VERONA study results. EyePoint has $118M in cash, expected to last into late Q3 2027, and plans to report DME trial results in early Q4 2027.

Stifel cuts EyePoint stock price target on trial setbacks

Stifel reduced its price target for EyePoint Inc. (EYPT) to $5.00 from $6.00, citing clinical trial setbacks. The company's stock is near its 52-week low, down 97% over the past year. EyePoint reported a larger-than-expected loss but exceeded revenue expectations in Q3 2026. The company has $118 million in cash and is focusing on its Duravyu treatment for diabetic macular edema.

EYPT sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 11 news stories mentioning EYPT (EyePoint, Inc.). Coverage has skewed bearish: 0 bullish, 2 neutral, and 9 bearish.

Recent EYPT coverage spans earnings, financial news and regulation.

What's driving EYPT

AlphAI scores every news story that mentions EYPT with an AI model for sentiment and relevance, and aggregates insider trades from EyePoint, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $EYPT

Score
$EYPTHighAI 8/10

EyePoint Pharma Earnings Call: DME Focus After Wet AMD Setback

EyePoint Pharma reported Q3 earnings, highlighting a setback in wet AMD trials and a 53% workforce reduction. Despite this, the company remains focused on DURAVYU for diabetic macular edema (DME), citing positive VERONA study results. EyePoint has $118M in cash, expected to last into late Q3 2027, and plans to report DME trial results in early Q4 2027.

$EYPTHighAI 8/10

Stifel cuts EyePoint stock price target on trial setbacks

Stifel reduced its price target for EyePoint Inc. (EYPT) to $5.00 from $6.00, citing clinical trial setbacks. The company's stock is near its 52-week low, down 97% over the past year. EyePoint reported a larger-than-expected loss but exceeded revenue expectations in Q3 2026. The company has $118 million in cash and is focusing on its Duravyu treatment for diabetic macular edema.

$EYPTMedAI 8/10Earnings

EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments

EyePoint, Inc. (EYPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments – Organizational focus on DURAVYU TM Phase 3 DME program; trials fully enrolled with topline data expected in early Q4 2027 – – DURAVYU DME program supported by the posit

Weekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win

AstraZeneca (AZN) received FDA approval for Ultomiris in IgA nephropathy, with a 43.4% reduction in proteinuria. Merck (MRK) got EU approval for KEYTRUDA plus Padcev in bladder cancer, showing a 35% reduction in death risk. Alvotech (ALVO) approved a new manufacturing process for SIMLANDI. Cytokinetics (CYTK) won Health Canada approval for MYQORZO in obstructive HCM. Viatris (VTRS) approved RYZUMVI for presbyopia. Enlivex (ENLV) and EyePoint (EYPT) announced significant workforce reductions.

Why AZN, VSXY, EYPT Stocks Are Moving Premarket Today

AstraZeneca (AZN) shares rose 1.8% premarket after Oracle (ORCL) announced a non-binding AI collaboration. Victoria’s Secret (VSXY) gained 1% following a Barclays price target increase to $112. EyePoint Pharmaceuticals (EYPT) fell 4.4% after JPMorgan downgraded it to 'Underweight' due to a clinical trial setback.

Related tickers